- |||||||||| Clinical, Journal: Clinical analysis of paraneoplastic neurological syndrome associated with thymoma (Pubmed Central) - May 1, 2019
The correlated antibody test and chest CT might be important in patients clinically suspected with neurological paraneoplastic syndrome or encephalitis with unknown reason. Surgical thymectomy combining with active immunological treatment may play a role in the favorable prognosis, even in those clinical severe patients.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Journal: Neurology (Pubmed Central) - Apr 30, 2019
A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis...The criteria for Lewy body dementia have been revised. Generic use of lamotrigine does not result in recrudescence of epileptic seizures or adverse effects.
- |||||||||| Journal: Subxiphoid robotic extended thymectomy - The first Indian report. (Pubmed Central) - Apr 30, 2019
Our experience suggests that subxiphoid approach offers a good operative view of the thymus in cervical region along with easy identification of bilateral phrenic nerves. Thus, SRT can be performed safely with comparable results.
- |||||||||| Biomarker, Journal, IO Biomarker: Myasthenia gravis: from autoantibodies to therapy. (Pubmed Central) - Apr 28, 2019
The findings reveal a previously unrecognized aetiopathogenic mechanism of thymic-hyperplasia-associated MG, evoking numerous questions that require further investigation. The recent immunological and pathological findings in myasthenia gravis promise to improve myasthenia gravis treatment, via the development of more precise and personalized therapies.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Rituxan (rituximab) / Roche, Biogen
Journal: Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. (Pubmed Central) - Apr 24, 2019
In very refractory cases, rituximab appeared to be effective, which has not been reported for the treatment of this condition before. No abstract available
- |||||||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring, NN1213 / Novo Nordisk
Phase classification: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Apr 20, 2019
P1, N=4, Terminated,
These findings implicate pathways not previously considered in extraocular muscle involvement in myasthenia gravis and will inform future studies. Phase classification: P=N/A --> P1
- |||||||||| Bridion (sugammadex) / Merck (MSD)
Clinical, Journal: Successful use of sugammadex for caesarean section in a patient with myasthenia gravis (Pubmed Central) - Apr 19, 2019
Myasthenia gravis especially when associated with pregnancy is a high-risk disease, and its course is unpredictable. We described the second report about use of sugammadex after rocuronium for a caesarean delivery with myasthenia gravis, but, unlike our case that formerly was diagnosed with myasthenia gravis, the patient was extubated on postoperative successfully and we did not encounter any respiratory problems.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Trial completion date, Trial primary completion date: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Apr 19, 2019
P3, N=117, Active, not recruiting,
We described the second report about use of sugammadex after rocuronium for a caesarean delivery with myasthenia gravis, but, unlike our case that formerly was diagnosed with myasthenia gravis, the patient was extubated on postoperative successfully and we did not encounter any respiratory problems. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- |||||||||| Journal: Assessment of pre and post-thymectomy myasthenia gravis. (Pubmed Central) - Apr 19, 2019
Modelling of the S102R variant change in the ChAT protein crystal structure suggests that the change affects protein structure and has a direct impact on the catalytic domain of the protein which abolishes embryo motility almost completely. Transcervical and transsternal thymectomy showed clinical benefits, however, there was no significant difference between them.
- |||||||||| Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Journal: Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. (Pubmed Central) - Apr 18, 2019
These results suggest that DCAFs could have utility in the development of new therapeutics against harmful antibodies. Alemtuzumab treatment can result in the development of neurologic autoimmune conditions that could mimic MS progression.
- |||||||||| Clinical, Journal: Clinical and genetic characterization of an Italian family with slow-channel syndrome. (Pubmed Central) - Apr 18, 2019
SCCMS is characterized by a broad and heterogeneous clinical phenotype in which disease onset, symptoms, severity, and progression can be highly variable even between family members. The identification of a CHRNE mutation allowed to make the definitive diagnosis of CMS in this family and contributed to define the clinical spectrum of this disease.
- |||||||||| Journal: Italian recommendations for diagnosis and management of congenital myasthenic syndromes. (Pubmed Central) - Apr 18, 2019
Because of the several therapeutic opportunities, CMS should be always considered in the differential diagnosis of neuromuscular disorders. The Italian Network on CMS proposes here recommendations for proper CMS diagnosis and management, aiming to guide clinicians in their practical approach to CMS patients.
- |||||||||| Retrospective data, Review, Journal: Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis. (Pubmed Central) - Apr 17, 2019
The Italian Network on CMS proposes here recommendations for proper CMS diagnosis and management, aiming to guide clinicians in their practical approach to CMS patients. Thymectomy may be considered effective in the treatment for non-thymomatous MG, with remission rate higher than for non-surgical treatment.
- |||||||||| Journal: A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era. (Pubmed Central) - Apr 17, 2019
Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.
- |||||||||| Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis (clinicaltrials.gov) - Apr 16, 2019
P3, N=44, Recruiting,
It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jun 2020
- |||||||||| Clinical, Retrospective data, Journal: Outcome of Extended Thymectomy in Myasthenia Crisis Patient. (Pubmed Central) - Apr 14, 2019
Patients with myasthenic crisis should have judicious drug adjustments under supervision and should be treated aggressively during impending myasthenic crisis. With modern management of myasthenia gravis, early surgery with myasthenic crisis is safe with good long-term outcomes.
- |||||||||| Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
Journal: Advances in autoimmune myasthenia gravis management. (Pubmed Central) - Apr 14, 2019
As a rare disease, clinical trials are challenged in patient recruitment. The great interest in development of treatments specific for MG is welcome, but decisions will need to be made to focus on those that offer significant benefits to patients.
- |||||||||| rivastigmine / generics
Preclinical, Journal: Efficacy of antidotes and their combinations in the treatment of acute carbamate poisoning in rats. (Pubmed Central) - Apr 12, 2019
As a consequence, increasing doses of atropine and their combination with hexamethonium assure excellent protection against physostigmine toxicity, while the best protection against pyridostigmine is provided by a strictly peripherally acting antinicotinic d-tubocurarine and bispyridinium oxime HI-6. The oxime acts as antidote against physostigmine and pyridostigmine poisoning by reactivating AChE in the brain and diaphragm, respectively.
- |||||||||| mycophenolate mofetil / Generic mfg.
Journal: Infections and the relationship to treatment in neuromuscular autoimmunity. (Pubmed Central) - Apr 11, 2019
There are few large studies investigating rates of infections in patients with autoimmune neuromuscular disorders and the relationship to immunomodulation. This study not only demonstrates the remarkably similar infection rates across the three diseases studied, but also shows their relationship to commonly used immunotherapies.
- |||||||||| Journal, HEOR: Factors associated with quality of life of people with Myasthenia Gravis. (Pubmed Central) - Apr 11, 2019
This study not only demonstrates the remarkably similar infection rates across the three diseases studied, but also shows their relationship to commonly used immunotherapies. The implications for clinical settings and the suggestions for future research are discussed.
- |||||||||| Journal: Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis. (Pubmed Central) - Apr 10, 2019
Our results showed that when we control for the influence of the ancestral haplotype 8.1, no polymorphism was demonstrated to be associated with EOMG development within the MHC region suggesting that the HLA-B*08:01 allele is the unique genetic factor within the HLA region responsible for EOMG development in patients who carry the ancestral haplotype 8.1. Our study also identified two novel polymorphisms as risk factors for MG HLA-B*08:01 positive patients which regulate the expression of the OVCH1 and CNYP2 genes.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
Journal: Eculizumab: A Review in Generalized Myasthenia Gravis. (Pubmed Central) - Apr 7, 2019
Eculizumab was generally well tolerated in these studies, with a tolerability profile similar to that reported previously in other indications. Although several questions remain, such as duration of treatment, cost effectiveness and long-term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gMG.
- |||||||||| Clinical, Journal, HEOR: The quality of life in patients with a different types of myasthenia gravis (Pubmed Central) - Apr 5, 2019
Favorable clinical type of myasthenia gravis was found in patients with weakness in extraocular and limb muscles. Factors associated with a poor quality of life included following: weakness in bulbar and respiratory muscles (p<0.003), endocrine comorbidities (p<0.01) or thymoma (p<0.005).
- |||||||||| Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system (Pubmed Central) - Apr 3, 2019
And only one patient was found severe infection with Pneumocystis carinii pneumonia. Rituximab is an effective and safe treatment strategy for patients with refractory and relapse autoimmune diseases of CNS, especially in neuromyelitis optica and myasthenia gravis.The adverse events including infection and allergy during infusion are not common.
|
